A pharmaceutical company focused on pet health has today announced it is to market the first canine pain management product delivered in a transmucosal mist form. Abbott (NYSE:ABT) announced today they have partnered with Velcera, Inc to bring to market the product – currently in clinical trials – which combines the proven pain medication meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) with Velcera’s patented Promist technology, and has been globally licensed for pain management in dogs.
Source: DogMagazine.net – the K9 Magazine blog
New Pain Management Product For Dogs on The Way
Related content:
